Brian D. Benneyworth, MD

Clinical Research Physician
Eli Lilly and Company

Poster(s):

• (16.07) Switching to tirzepatide 5 mg from GLP-1 RAs: Clinical expectations in the first 12 weeks of treatment
  Friday, May 10, 2024

  3:05 PM – 3:20 PM CDT